A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
MARCH 24th IS WORLD TB DAY
March 24th is designated as World TB Day, a time to remember and build awareness around tuberculosis, which remains an epidemic in many parts of the world. This World TB Day we strive the find the missing 3 million cases of TB per year that go undiagnosed. Of these, an estimated 344,000 cases had MDR-TB in 2013. Major efforts are needed to close this gap and scale-up treatment for those most at need.
Recent News and Announcements
endTB, a collaboration between Partners in Health, Médecins Sans Frontières,Interactive Research and Development, and the financial partner UNITAID, will kick off next month. The project aims to radically change the management of MDR-TB and will provide access to new anti-TB drugs to 2,600 patients in 16 countries. Read the press release from MSF here.
We want to hear about your experience! Our aim is to compile experiences of both successful and unsuccessful efforts to gain access to new TB drugs through compassionate use, expanded access, or other pre-approval mechanisms. We hope to gather information on effective strategies and potential roadblocks to accessing new TB drugs. Access our survey here, […]
Médecins Sans Frontières (MSF), Treatment Action Campaign (TAC), Treatment Action Group (TAG) and others are calling on global health actors to step up and ensure new and repurposed DR-TB drugs reach people who are otherwise without treatment options. ** SIGN ON LETTER ** to global actors and drug companies New drugs to treat drug-resistant tuberculosis (DR-TB) […]
TB Alliance has announced the Phase I trial of TBA-354, the first TB drug to have advanced to Phase I trials in 6 years. Recruitment for the Phase I randomized, double-blind trial is under way. The trial plans to enroll 50 US volunteers and evaluate the safety, tolerability, pharmacokinetics, and dosing of TBA-354. In pre-clinical studies, […]
This month, Nature Medicine reported on Otsuka’s compassionate use program of delamanid. Delamanid has been approved by regulators in Japan, South Korea and the European Medicines Agency. The drug is available on a limited basis in other countries through Otsuka’s compassonate use program; however, the company has refused to provide delamanid if it is in combination with bedaquiline. […]